key: cord-0875297-0z852wf6
authors: Saxena, Shailendra K.; Kumar, Swatantra; Ansari, Saniya; Paweska, Janusz T.; Maurya, Vimal K.; Tripathi, Anil K.; Abdel‐Moneim, Ahmed S.
title: Transmission dynamics and mutational prevalence of the novel Severe acute respiratory syndrome coronavirus‐2 Omicron Variant of Concern
date: 2022-02-04
journal: J Med Virol
DOI: 10.1002/jmv.27611
sha: c0b17b446ba29985b51389f15f907ccf53d0b3b3
doc_id: 875297
cord_uid: 0z852wf6

The novel Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) variant, Omicron (PANGO lineage B.1.1.529) is being reported from all around the world. The WHO has categorized Omicron as a Variant of Concern (VOC) considering its higher transmissibility and infectivity, vaccine breakthrough cases. As of January 6, 2022, Omicron has been reported in at least 149 countries. Therefore, this study was planned to investigate the transmission dynamics and mutational prevalence of the novel SARS‐CoV‐2 Omicron variant. The transmission dynamics and Omicron SARS‐CoV‐2 divergence was studied using GISAID and Nextstrain which provides information about the genetic sequences, epidemiological, geographical, and species‐specific data of human, avian, and animal viruses. Further, the mutation prevalence in spike glycoprotein of Omicron was studied, and the frequency of the crucial mutations was compared with the other prevalent VOCs. The transmission dynamics suggest that the Omicron was first identified in South Africa and then it was reported in the United Kingdom followed by the United States and Australia. Further, our phylogenetic analysis suggests that Omicron (BA.1) was clustered distinctly from the other VOCs. In the Spike glycoprotein, the Omicron (B.1.1.529) demonstrates critical 32 amino acid changes. This study may help us to understand mutational hotspots, transmission dynamics, phylogenetic divergence, effect on testing and immunity, which shall promote the progress of the clinical application and basic research.

(VOI), and Variants under monitoring (VUM) to focus global research and awareness, as well as to lead the on-going worldwide responses to the COVID-19 pandemic. 2 Subsequently, the Omicron has been transmitted to Belgium, Israel, Botswana, and Hong Kong. By November 29, 2021, the Omicron was spread in Australia, Austria, the Czech Republic, Belgium, Canada, Italy, Denmark, France, Germany, the Netherlands, and the United Kingdom. 6, 7 According to the WHO, as of January 6, 2022, the Omicron variant is reported in at least 149 countries. 8 Omicron has a significant growth advantage over the Delta variant and it spreads rapidly than Delta, in countries with known community transmission with a doubling period of 1.5-3 days. 9 This causes worries about the novel variant's greater transmissibility and infectivity, as well as its ability to evade immunity established by natural infections or vaccination. 10 Therefore, the present study was planned to investigate the transmission dynamics, phylogenetic analysis, and mutation prevalence of Omicron SARS-CoV-2 that may help us establish effective preventive and therapeutic strategies in the forthcoming COVID-19 waves. 11 Considering the higher transmissibility, the management of the forthcoming pandemic is crucial to achieve 12 along with implementation of restriction guidelines as it was implemented in the previous outbreaks. 13 2 | MATERIALS AND METHOD

To study the transmission dynamics of Omicron, we have used GI-SAID (https://www.gisaid.org/hcov19-variants/). GISAID provides information about the genetic sequences, epidemiological, geographical, and species-specific data of human, avian, and animal viruses. The transmission lines were analyzed to understand the transmission dynamics of Omicron in various countries. 14,15

To determine the Omicron SARS-CoV-2 divergence, we employed the Nextstrain, which offers the most recent worldwide genomic sequencing of the SARS-CoV-2 data as soon as it is released by GISAID (https://www.gisaid.org/). Phylogenetic tree analysis was performed to observe the mutational divergence of Omicron SARS-CoV-2 in the unrooted tree. 16 

To determine the mutation prevalence in spike glycoprotein of Omicron, we have analyzed the frequencies of amino acid substitutions reported on SARS-CoV-2 (hCoV-19) Mutation Reports (https://outbreak.info/ compare-lineages?pango=Alpha%26gene=S%26threshold=0.2). The frequency of the crucial mutations was compared with the other prevalent VOCs. 17 

To identify the most significant mutations in the Omicron, we have taken 60 410 Omicron sequences and performed the χ 2 test analysis where the prevalence of specific mutation was considered as the observed value and the expected value was considered to be 100. If the null hypothesis is true, the observed and expected frequencies will be close in value and the χ 2 statistic will be close to zero. If the null hypothesis is false, then the χ 2 statistic will be large.

Omicron-specific cases increase exponentially and spread worldwide within days of initial identification. 18 Transmission dynamics showing the widespread transmission of novel SARS-CoV-2 Omicron ( Figure 1A ). The transmission dynamics suggest that the Omicron was first identified in South Africa ( Figure 1B ) and then it was reported in the United Kingdom ( Figure 1C ) followed by the United States ( Figure 1D ). Subsequently, the cases were reported from various countries ( Figure 1E VOCs. 19, 20 The temporal change in the number of Omicron cases in a population was measured with or with pre-existing immunity. Delta quickly replacing other variants to prevail globally, including in South Africa. 24 

The SARS-CoV-2 spike glycoprotein interacts with human ACE2 receptors for attachment and internalization. 25 ( Table 1 ). These data suggest that these mutations are not prevalent in Omicron.

The WHO has categorized the COVID-19 Omicron variant as a variant of concern, based on evidence that it has various alterations that might affect its transmissibility and pathogenicity, vaccine effective- The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

The authors declare that there are no conflict of interests. 

The authors confirm that the data supporting the findings of this study are available within the article.

http://orcid.org/0000-0003-2856-4185

Omicron emerges

Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) Variant of Concern and its global perspective

World Health Organization. Naming SARS-CoV-2 Variants. Accessed on

Omicron (B.1.1.529) Variant. Accessed on 28

Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern

Transmission of Omicron (B.1.1.529) -SARS-CoV-2 Variant of Concern in a designated quarantine hotel for travelers: a challenge of elimination strategy of COVID-19

COVID-19 Genomics UK (COG-UK) Consortium, Peacock SJ, Robertson DL. SARS-CoV-2 variants, spike mutations and immune escape

Enhancing Response to Omicron (COVID-19 Variant B.1.1.529): Technical Brief and Priority Actions for Member States

Emergence of new SARS-CoV-2 Variant of Concern Omicron (B.1.1.529) -highlights Africa's research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts

Structural and molecular perspectives of SARS-CoV-2

Therapeutic approaches for SARS-CoV-2 infection

Epidemiologic characteristics, clinical management, and public health implications of Coronavirus disease 2019 (COVID-19) in pregnancy: a systematic review and meta-analysis

Effect of easing lockdown and restriction measures on COVID-19 epidemic projection: a case study of Saudi Arabia

GISAID's role in pandemic response

disease and diplomacy: GISAID's innovative contribution to global health

Global Initiative on Sharing All Influenza Data-from vision to reality

Variant Report Hughes and the Center for Viral Systems Biology 2022

High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

The biological and clinical significance of emerging SARS-CoV-2 variants

Genomic Epidemiology of Novel Coronavirus -Global Subsampling 2022

The new SARS-CoV-2 strain shows a stronger binding affinity to ACE2 due to N501Y mutant

Omicron (B.1.1.529) Variant. Accessed on 02

World Health Organization. Tracking SARS-CoV-2 variants

Sequence analysis of the emerging SARS-CoV-2 Variant Omicron in South Africa

Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy

Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus

Tracking the international spread of SARS-CoV-2 lineages B.1.1.7 and B.1.351/501Y-V2 with Grinch

Omicron (B.1.1.529): infectivity, vaccine breakthrough, and antibody resistance

Public health implications of SARS-CoV-2 variants of concern: a rapid scoping review

The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron

European Centre for Disease Prevention and Control. Implications of the Emergence and Spread of the SARS-CoV-2 B.1.1. 529 Variant of Concern (Omicron), for the EU/EEA. 26

Transmission dynamics and mutational prevalence of the novel Severe acute respiratory syndrome coronavirus

Omicron Variant of Concern